Kiniksa Pharmaceuticals International (KNSA) Preferred Stock Liabilities (2017 - 2018)
Kiniksa Pharmaceuticals International (KNSA) reported Preferred Stock Liabilities of $310.6 million for Q1 2018, up 159.32% quarter-over-quarter from $119.8 million in Q4 2017.
Kiniksa Pharmaceuticals International (KNSA) Preferred Stock Liabilities (2017 - 2018) Analysis & Trends
Kiniksa Pharmaceuticals International has reported Preferred Stock Liabilities for 2 years, with the latest figure at $310.6 million in Q1 2018.
- For the quarter ending Q1 2018, Preferred Stock Liabilities changed N/A year-over-year to $310.6 million; the trailing twelve-month figure through Mar 2018 stood at $310.6 million (changed N/A YoY), and the FY2017 full-year result was $119.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q1 2018 stood at $310.6 million, up from $119.8 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $310.6 million in Q1 2018, with the low at $119.8 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Kiniksa Pharmaceuticals International | 3.73 Bn | 3.26 Bn | 193.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 310.59 Mn |
| Dec 31, 2017 | 119.77 Mn |